Dina Pharma is a pre-clinical stage company developing a treatment for Levodopa-Induced Dyskinesia (LID) – an orphan disease state.
Our lead program, DPI-289, for LID associated with Parkinson’s disease (PD) meaningfully improves upon the current gold-standard treatment, with fewer side effects.
DPI-289 is a small-molecule NCE, with a novel mechanism of action referred to as DAMA (delta agonist, mu antagonist). Robust efficacy data in non-human primate models indicate DPI-289 may reduce dyskinesia and prolong the effect of Levodopa.
Dina Pharma has a lean and experienced team supported by Michael J. Fox Foundation and partnerships with world-renowned neurologists and experts in Parkinson's disease.